Skip to main content

Table 2 Characteristics of studies included in this meta-analysis

From: Prognostic significance of pretreatment controlling nutritional status score in urological cancers: a systematic review and meta‐analysis

Study, year Country Duration Sample size Median follow-up (months) cancer type Stage Treatment Study design Survival outcome Cut-off NOS
Guo 2017 China 2010–2011 189 45 BC Mixed Surgery R OS 3 7
Miyake 2017 Japan 2006–2016 117 NR BC Non-metastatic Surgery R OS,CSS 1 8
Zhang 2019 Chian 2015–2017 94 16.31 PC Metastatic Surgery R PFS 3 7
Elghiaty 2019 Egypt 2005–2014 1046 63 RCC Non-metastatic Surgery R OS,CSS,RFS 2 8
Kang 2018 1 Korean 1999–2015 1418 41 RCC Mixed Surgery R CSS 2 7
Kang 2018 2 Korean 1999–2015 1282 41 RCC Non-metastatic Surgery R RFS 2 7
Song 2019 China 2010–2012 325 64 RCC Non-metastatic Surgery R OS,CSS,DFS 3 8
Takemura 2020 Japan 2016–2019 49 26.4 RCC Metastatic Target therapy R CSS,PFS 2 7
Zheng 2018 China 2004–2014 635 48.4 RCC Non-metastatic Surgery R OS,CSS 2 8
Ishihara 2017 Japan 2003–2014 107 Mean:
41.48
UTUC Non-metastatic Surgery R OS,CSS,RFS 3 7
Xu 2018 China 2004–2016 572 41 UTUC Mixed Surgery R OS,CSS,RFS 2 8
Bao 2020 China 1999–2015 408 32 UTUC Non-metastatic Surgery R OS,CSS,DFS 3 8
Suzuki 2020 Japan 2003–2018 163 12.3 UC Metastatic Mixed R OS 2 8
  1. BC bladder cancer, PC prostate cancer, RCC renal cell carcinoma, UTUC upper tract urinary cancer, UC urothelial cancer, NR not reported, R retrospective, OS overall survival, CSS cancer-specific survival, DFS disease-free survival, RFS recurrence-free survival, PFS progress-free survival, NOS Newcastle-Ottawa Scale